April 7 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O:
RHYTHM PHARMACEUTICALS ANNOUNCES PIVOTAL PHASE 3 TRANSCEND TRIAL MEETS PRIMARY ENDPOINT WITH -19.8% PLACEBO-ADJUSTED BMI REDUCTION IN PATIENTS (N=120) WITH ACQUIRED HYPOTHALAMIC OBESITY
RHYTHM PHARMACEUTICALS INC - SETMELANOTIDE THERAPY ACHIEVES -16.5% MEAN BMI CHANGE IN PATIENTS
RHYTHM PHARMACEUTICALS INC - SETMELANOTIDE ACHIEVES -19.2% PLACEBO-ADJUSTED BMI REDUCTION IN ADULTS
RHYTHM PHARMACEUTICALS INC - REGULATORY SUBMISSIONS IN U.S. AND EU EXPECTED Q3 2025
RHYTHM PHARMACEUTICALS INC - PRIMARY ENDPOINT ACHIEVED WITH -16.5% MEAN BMI REDUCTION
RHYTHM PHARMACEUTICALS INC - NO NEW SAFETY SIGNALS OBSERVED WITH SETMELANOTIDE
Source text: ID:nGNX6NQcwV
Further company coverage: RYTM.O
(((( Reuters.briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.